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        Multiple sclerosis (MS) is characterized by re-
peated episodes of infl  ammation and demyelin-
ation in the central nervous system (CNS) with 
varying degrees of axonal loss (  1  ). Although 
chronic disability in MS was traditionally attrib-
uted to demyelination, axonal loss is now re-
garded as the major pathological correlation to 
the development of permanent neurological de-
fi  cits (  2, 3  ). Axonal injury is most pronounced in 
regions of active infl  ammation and demyelin-
ation (  4, 5  ), but it is currently unknown whether 
this axonal pathology is caused by loss of trophic 
support of the oligodendrocyte, toxic infl  amma-
tory mediators, or a specifi  c immune response 
against axonal antigens (  6  –  10  ). 
  The presence of Ig  ’  s and complement ac-
tivation products in active MS lesions (  11, 12  ) 
and the effi   cacy of therapeutic plasma exchange, 
or treatment with B cell  –  depleting antibodies, 
in some patients (  13  –  15  ) provide circumstantial 
evidence for the involvement of antibodies in 
MS. However, the identity of antigens targeted 
by clinically relevant antibodies in MS remains 
obscure. Most studies have focused on the role 
of myelin-specifi  c autoantigens such as myelin 
oligodendrocyte glycoprotein (MOG), galac-
tosyl ceramide, or sulphogalactosyl ceramide 
that provide targets for autoantibody-mediated 
demyelination in experimental autoimmune 
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  Axonal injury is considered the major cause of disability in patients with multiple sclerosis 
(MS), but the underlying effector mechanisms are poorly understood. Starting with a 
proteomics-based approach, we identifi  ed neurofascin-specifi  c autoantibodies in patients 
with MS. These autoantibodies recognize the native form of the extracellular domains of 
both neurofascin 186 (NF186), a neuronal protein concentrated in myelinated fi  bers at 
nodes of Ranvier, and NF155, the oligodendrocyte-specifi  c isoform of neurofascin. Our in 
vitro studies with hippocampal slice cultures indicate that neurofascin antibodies inhibit 
axonal conduction in a complement-dependent manner. To evaluate whether circulating 
antineurofascin antibodies mediate a pathogenic effect in vivo, we cotransferred these 
antibodies with myelin oligodendrocyte glycoprotein  –  specifi  c encephalitogenic T cells to 
mimic the infl  ammatory pathology of MS and breach the blood  –  brain barrier. In this animal 
model, antibodies to neurofascin selectively targeted nodes of Ranvier, resulting in deposition 
of complement, axonal injury, and disease exacerbation. Collectively, these results identify 
a novel mechanism of immune-mediated axonal injury that can contribute to axonal 
pathology in MS. 2364 AUTOANTIBODIES TO NEUROFASCIN INDUCE AXONAL INJURY | Mathey et al.
(one with an autoimmune peripheral neuropathy and the 
other with cardiomyopathy). This approach identifi  ed a se-
ries of spots migrating with an apparent molecular mass of 
155 kD that was recognized by the IgG fractions from all fi  ve 
MS patients but neither of the controls (  Fig. 1 B  ). Two spots 
were excised from the gels, and the immunoreactive target 
was identifi  ed as neurofascin by mass spectrometry (sequence 
coverage of 23% and a probability of 1.9 e       34  ). 
  Having identifi  ed NF155 as a candidate autoantigen in 
MS, we reexamined the disease specifi  city of this serum anti-
body response in additional MS patients (  n     26), OIND 
patients (  n     17), and control blood donors (  n     21) by 
ELISA (  Fig. 1, C and D  ). Approximately one third of MS pa-
tients and occasional OIND patients and control donors had 
a high titer response to the extracellular domain of NF155 
(NF155  ED  ;   Fig. 1, C and D  ). When MS patients were strati-
fi  ed according to disease course, it became evident that the 
highest levels of NF155  ED  -specifi  c antibodies were found in 
the sera of patients with chronic progressive disease (median 
OD   0.69) as compared with relapsing-remitting MS (me-
dian OD   0.10), OIND (median OD   0.10), and blood 
donor controls (median OD   0.25). We next purifi  ed anti-
NF155  ED   antibodies by immunoaffi   nity chromatography 
from the plasma of three representative high titer MS patients 
to determine whether these antibodies recognized the native 
protein when expressed at the surface of NF155-transfected 
cells. This was indeed the case, but purifi  ed NF155  ED  -specifi  c 
antibodies also bound to NF186-transfected cells, as demon-
strated by fl  ow cytometry (  Fig. 1 E  ). This cross-reactivity was 
confi  rmed by Western blotting of total brain homogenate 
(  Fig. 1 F  ) and led us to speculate that recognition of NF186 
at the node of Ranvier by these antibodies might exacerbate 
axonal injury and accelerate disease progression. 
  Antineurofascin antibodies exacerbate clinical disease 
in EAE, an animal model of MS 
  To investigate this hypothesis, we developed a cotransfer 
model of T cell  –  mediated EAE (  16  ) in which rats were in-
jected at disease onset with the panneurofascin IgG2a mAb 
A12/18.1. This antibody mimics the properties of NF155  ED  -
specifi  c antibodies purifi  ed from MS patients in that it recog-
nizes the extracellular domains of both NF155 and NF186, 
as demonstrated by fl  ow cytometry of live neurofascin-trans-
fected cell lines (unpublished data). Treatment with 500      g 
A12/18.1 i.p. at disease onset resulted in a rapid and substan-
tial increase in disease severity within 24 h, by which time 
the clinical score of antineurofascin-treated animals was 2.5       
0.18 (mean       SEM;   n     23). In comparison, control ani-
mals injected with an irrelevant mouse IgG2a antibody had 
a clinical score of 1       0.12 (mean       SEM;   n     23;   Fig. 2 A  ).   
All animals survived this acute exacerbation of disease and 
began to show signs of clinical recovery 5 d after antibody 
transfer. The majority of animals subsequently regained com-
plete motor function within 2 wk and exhibited no residual 
signs of disease. However, despite exhibiting some initial 
signs of clinical improvement, a proportion of the animals 
encephalomyelitis (EAE), an animal model of MS (  16  –  21  ). 
Despite several studies that have documented autoantibody 
responses to neuronal and axonal antigens in MS, their func-
tional importance has gone largely unexplored (  9, 22-25  ). 
  Our present study was inspired by fi  ndings obtained using 
a proteomic approach to explore the specifi  city of the myelin-
reactive autoantibody repertoire in MS patients. We identifi  ed 
several patients who showed a conspicuous antibody response 
to neurofascin present in our myelin preparations. 
  Neurofascin exists in two isoforms: neurofascin 155 (NF155) 
is a myelin protein localized at the paranodal axo  –  glial junc-
tion, whereas NF186 is a neuronal protein exposed on the sur-
face of myelinated axons at the axonal initial segment and node 
of Ranvier (  26  ). NF186 associates with the      1 and      3 chains 
of voltage-gated sodium channels (  27  ) and other nodal pro-
teins to maintain the unique molecular architecture of the node 
of Ranvier necessary for saltatory conduction (  26  ). 
  The neurofascin-specifi  c autoantibody response in MS 
patients recognized the extracellular domain of both NF155 
and NF186, prompting us to investigate the functional eff  ects 
of such a panneurofascin-specifi  c antibody response both 
in vitro and in an animal model. Cotransfer of a panneurofas-
cin mAb together with MOG-reactive T cells demonstrated 
that antineurofascin antibodies can exacerbate disease sever-
ity in EAE by binding selectively to NF186 at the node of 
Ranvier. This results in acute, but reversible, axonal injury 
and is associated with codeposition of C9 and mouse mAb 
at nodes of Ranvier. In vitro, the neurofascin-specifi  c anti-
body was able to induce an electrophysiological defi  cit in 
hippocampal slices only in the presence of fresh sera, in-
dicating that its pathogenic eff  ect in vivo is complement 
dependent. These observations identify NF186 as a target for 
autoantibody-mediated axonal injury, a novel pathomechanism 
that may contribute to the development of axonal pathology 
in MS. 
    RESULTS   
  Identifi  cation of neurofascin as a candidate autoantigen 
in MS 
  To quantitatively identify minor myelin glycoproteins recog-
nized by autoantibodies in patients with MS, we used a glyco-
protein fraction isolated from human myelin by lentil-lectin 
affi   nity chromatography that is highly enriched for known 
myelin antigens such as MOG, as well as other as yet poorly 
characterized myelin-associated glycoproteins (  Fig. 1 A  ).   
Western blotting after SDS-PAGE with sera from 22 MS 
  patients and 21 control patients (10 with other neurological 
diseases and 11 with other infl  ammatory neurological diseases 
[OINDs]) revealed a marked interpatient variability in the 
immunoreactive band pattern (not depicted); however, in 
    20% of MS samples we observed a prominent response to 
components migrating in the molecular mass range of 150  –
  180 kD (  Fig. 1 A  ). To identify this protein, myelin glyco-
proteins were separated by two-dimensional gel electrophoresis, 
and were probed after Western blotting using purifi  ed IgG 
(  28  ) obtained from fi  ve MS patients and two control donors JEM VOL. 204, October 1, 2007 
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  Transfer of the panneurofascin-specifi  c antibody results 
in acute axonal damage in the absence of demyelination 
or increased infl  ammation in the CNS 
  We performed extensive histological and immunopathologi-
cal analysis of the CNS to determine how A12/18.1 exacer-
bated clinical disease in animals with EAE. We could fi  nd 
no evidence that the mAb had any signifi  cant eff  ect on either 
(27%;   n     11) treated with A12/18.1 died suddenly during 
this recovery period (  Fig. 2 B  ). This was not seen in animals 
treated with the control mouse IgG2a mAb, nor has it been 
reported in other cotransfer models of EAE. In the absence of 
a preexisting infl  ammatory response in the CNS, the transfer 
of the neurofascin-specifi  c mAb into naive recipients (  n     7) 
resulted in no clinical defi  cit. 
  Figure 1.     Antibodies to NF155 and NF186 are present in patients with MS. (A) Human myelin and the myelin glycoprotein (gp) fraction were 
separated by SDS-PAGE and blotted, and glycoproteins were detected using biotinylated lentil-lectin. The myelin glycoprotein fraction is highly enriched 
in higher molecular mass glycoproteins (left). Using this myelin glycoprotein fraction to screen patient sera by Western blotting identifi  ed antibody 
responses to a variety of components, including a protein migrating with an apparent molecular mass of     155 kD (right). (B) Two two-dimensional gels 
were run in parallel. One was silver stained (left) and the other was blotted and developed with IgG obtained from an immuno  adsorption eluate of an 
MS patient (right). The encircled spots at 155 kD were excised and identifi  ed by MALDI-MS as neurofascin. (C) Serum IgG antibody titers to recombinant 
NF155  ED   were measured by ELISA in OIND (  n     17) and MS (  n     26) patients stratifi  ed by the disease course. Patients with chronic progressive MS 
(MS-CP) had the highest median antibody response (horizontal lines) to NF155  ED  , which was signifi  cantly higher than in OIND patients. *, P       0.05 using the 
Mann-Whitney U test. (D) The titrations of three sera from high titer MS patients and one negative control donor are shown. (E) Anti-NF155  ECD   antibodies 
affi  nity purifi  ed from plasma of an MS patient bind to both isoforms of neurofascin when expressed at the surface of transfected cells (left, NF155; right, 
NF186), as shown by fl  ow cytometry. The open graph represents the staining of the control cell line, and the shaded graph represents the staining of the 
neurofascin transfectants. (F) Rat brain homogenate was separated by SDS-PAGE, blotted, and probed with either the neurofascin-specifi  c mAb A12/18.1 
or the purifi  ed anti-NF155  ECD   antibodies, indicating recognition of both the 155- and 186-kD isoforms.     2366 AUTOANTIBODIES TO NEUROFASCIN INDUCE AXONAL INJURY | Mathey et al.
neurofascin-specifi  c antibody. This was not observed in control 
IgG2a-treated animals with EAE in which      -APP immuno-
reactivity was minimal and restricted to sites of perivascular 
and sub-pial infl  ammation. After complete clinical recovery, 
     -APP immunoreactivity had returned to background levels 
indicating resolution of axonal damage. Occasional degener-
ating myelin fi  gures were observed in only one animal, and 
we observed no obvious reduction in axonal density in the 
spinal cord after clinical recovery. 
  Binding of antibody to neurofascin in vivo is restricted 
to the node of Ranvier 
  Our data indicate that the clinical exacerbation induced by 
A12/18.1 is mediated by a direct eff  ect of the antibody on 
the axon. This suggests that the primary target is NF186 at 
the node of Ranvier rather than the myelin/oligodendroglial 
isoform of NF155. This was confi  rmed by identifying sites at 
which A12/18.1 was bound within the CNS of animals with 
EAE by laser scanning confocal microscopy (  Fig. 4  ).   
  30 h after antibody transfer, deposition of A12/18.1 was 
restricted to distinct bands in longitudinal sections (  Fig. 4 B  ) 
or appeared as occasional circular profi  les in transverse sec-
tions. No deposition of mouse IgG2a was detected in the 
CNS of animals injected with the control antibody (  Fig. 4 A  ). 
Triple staining using antibodies to specifi  c nodal and paranodal 
antigens demonstrated that deposition of the mouse neuro-
fascin-specifi  c mAb was restricted to nodes of Ranvier, where 
it colocalized with voltage-gated sodium channels (  Fig. 4, 
C  –  F  ). We observed no colocalization of adoptively trans-
ferred A12/18.1 with NF155 within the paranodal domain of 
myelinated fi  bers (  Fig. 4 B  ), whereas the mAb will bind both 
isoforms of neurofascin in vitro and can be used to identify 
NF155 within the paranodal domains of myelinated fi  bers in 
fi  xed tissue sections (not depicted). 
  In animals treated with A12/18.1, we observed a distinct 
halo of C9 deposition restricted to the immediate vicinity of 
antibody bound to the node (  Fig. 4, G and H  ). This was not 
observed in animals with EAE treated with the control mouse 
IgG2a antibody and suggests that complement may play an 
important role in antibody-mediated axonal injury in this 
model system. 
  Antineurofascin antibodies inhibit neurotransmission 
in vitro 
  The ability of the neurofascin-specifi  c mAb to disrupt nerve 
conduction was examined in rat hippocampal slices in vitro. 
Perfusion of hippocampal slices with 20      g/ml A12/18.1 in 
the presence of 2.5% fresh rat serum had a considerable eff  ect 
on axonal conduction as measured by the presynaptic fi  ber 
volley (essentially a compound action potential) recorded from 
the Schaff  er collateral-commissural fi  bers. After a variable 
delay of between 15 and 50 min (  Fig. 5, A and B  ), we ob-
served a      50% reduction in the amplitude of the fi  ber volley 
(  Fig. 5 C  ).   This eff  ect was abolished if the serum was heat 
inactivated before the experiment at 56  °  C for 30 min to de-
stroy complement (  Fig. 5 C  ). In addition, there was no eff  ect 
infl  ammation or demyelination (  Figs. 2 B   and   3, A  –  D  ).   Com-
parison of the infl  ammatory response revealed that this was 
similar in both A12/18.1-treated and control animals both 
with respect to the numbers of infl  ammatory foci, as well as 
the numbers of T cells and macrophages infi  ltrating the CNS 
(  Figs. 2 B   and   3, A and B  ). However, the disease exacerbation 
induced by A12/18.1 was associated with a marked increase 
in immunoreactivity for      -amyloid precursor protein (     -APP), 
a marker of acute axonal injury (  Figs. 2 B   and   3, E  –  H  ). The 
accumulation of      -APP refl  ects disruption of axonal transport 
at sites of axonal injury and was often observed in areas devoid 
of infi  ltrating infl  ammatory cells in animals treated with the 
  Figure 2.     Passive transfer of antineurofascin antibody exacerbates 
adoptive transfer EAE. (A) Rats injected with 2       10 6   activated  MOG IgD -
specifi  c T cells followed by 500      g IgG2a control antibody on d 4 (open 
circles) reached a maximum clinical score of 1       0.12 and had completely 
recovered by day 10 after T cell transfer. Disease activity was exacerbated in 
rats coinjected with antineurofascin mAb (closed squares). These animals 
reached a maximum clinical score of 2.7       0.17, and clinical recovery was 
still incomplete 20 d after T cell transfer. Data are reported as the mean       SEM. 
(  n     11). Pooled data from independent experiments are shown. (B) Cotransfer 
of the NF155/186-specifi  c mAb in rats with adoptively transferred EAE 
increased disease severity without exacerbating either infl  ammation or 
demyelination in the CNS. Neither the infl  ammatory index (P   0.25) nor the 
number of T cells identifi  ed with W3/13 (P   0.84) or the number of macro-
phages identifi  ed with ED1 (P   0.41) was increased in the animals treated 
with the NF155/186-specifi  c mAb. In contrast, axonal damage was augmented, 
as seen by      -APP staining (P   0.009). Clinical data are pooled from inde-
pendent experiments. Histological data were obtained from animals killed 
48 h after mAb injection. Data are reported as the mean       SEM.  Comparison 
of groups was statistically evaluated with Mann-Whitney U test.    JEM VOL. 204, October 1, 2007 
ARTICLE
2367
disease remain obscure. Previous studies demonstrated that 
axonal injury is most pronounced in areas of infl  ammatory 
demyelination. This led to the concept that axonal loss was 
a nonspecifi  c   “  bystander  ”   response to infl  ammatory demye-
lination mediated by soluble factors generated by activated 
macrophages such as nitric oxide or T cells (  10, 29  ). However, 
although infl  ammatory demyelination is a ubiquitous feature 
when the hippocampal slices were perfused with fresh serum 
and a control mouse IgG2a mAb (  Fig. 5 C  ). 
    DISCUSSION   
  Axonal loss is responsible for the development of chronic neuro-
logical defi  cits in MS, but the pathomechanisms that initiate 
or exacerbate axonal injury in this infl  ammatory demyelinating 
  Figure 3.     Pathology associated with autoantibody-mediated axonal injury in adoptive transfer EAE. Representative histopathology of the 
spinal cord 2 d after transfer of either antineurofascin antibody (B, D, F, and H) or an IgG2a control antibody (A, C, E, and G). (A and B) Hematoxylin and 
eosin staining reveals the presence of similar numbers of infl  ammatory infi  ltrates (arrows) in animals coinjected with (A) control mAb and (B) NF155/186-
specifi  c mAb. Arrowheads indicate areas in A and B that are shown in immunohistochemical staining for      -APP (E and F) at a higher magnifi  cation. 
(C and D) Luxol fast blue staining for myelin (blue/turquoise) reveals that demyelination is not enhanced by the antineurofascin mAb. In E  –  H,     -APP 
is stained brown by immunohistochemistry, and cell nuclei are counterstained blue with hematoxylin. This staining for      -APP, which indicates acute 
axonal injury, reveals numerous injured axons (brown dots in cross sections, F; brown fibers in longitudinal sections, H) in animals treated with 
the NF155/186-specific mAb. Note that in comparison with animals treated with the NF155/186-specific mAb (F and H), axonal injury is virtually 
absent in animals receiving the control IgG2a mAb (E and G). Arrows in H indicate brown     -APP – positive  axons.  Bars:  (A – D)  220      m; (E  –  H) 30      m; 
(E and F, insets) 13      m.   2368 AUTOANTIBODIES TO NEUROFASCIN INDUCE AXONAL INJURY | Mathey et al.
structural and functional integrity of myelinated fi  bers (  26  ). 
These isoforms are derived from a single gene by alternative 
splicing, and their extracellular domains contain six identical 
Ig domains and a variable number of identical fi  bronectin-
like repeats, diff  ering only in that NF155 uses an alternative 
fi  bronectin type III repeat and lacks a mucin-like domain 
(  33  ). As a consequence, mAbs raised against these proteins are 
commonly cross-reactive. This is also the case for the auto-
antibody response to neurofascin in patients with MS, which 
recognizes the intact extracellular domains of both NF155 and 
NF186, as we demonstrate by fl  ow cytometry. 
of MS, axonal loss does not necessarily correlate with lesion 
distribution and load in defi  ned spinal cord tracts (  30  ) and 
continues despite resolution of CNS infl  ammation in patients 
with progressive disease (  31, 32  ). These observations led to 
suggestions that, in addition to the eff  ects of infl  ammation, 
other mechanisms are involved in the development of axonal 
pathology in MS. 
  Using an unbiased proteomic approach, we identify 
neurofascin as a novel target of autoantibodies in MS. Neuro-
fascin is a member of the L1 family of cell adhesion molecules, 
and its two isoforms play essential roles in maintaining the 
  Figure 4.     The panneurofascin-specifi  c mAb A12.18/1 binds selectively to the node of Ranvier in vivo in animals with EAE. Confocal microscopy 
of representative spinal cord tissue from animals with EAE 30 h after transfer of anti-NF155/NF186 mAb A12.18/1 (B  –  H) or IgG2a control antibody (A). 
Cotransfer of anti-NF155/NF186 mAb resulted in deposition of the antibody within discreet regions of the CNS when visualized with an Alexa Fluor 
488  –  conjugated anti  –  mouse IgG2a antibody (green). Double staining with a rabbit antibody to NF155 (red) identifi  ed the paranodal domains of myelin-
ated axons and demonstrated that the injected mAb did not colocalize with NF155 but was deposited between adjacent paranodes (B).There was no 
deposition of mouse antibody in the CNS of animals injected with the isotype control antibody when visualized with an Alexa Fluor  488 – conjugated 
anti  –  mouse IgG2a antibody (green), as shown in relation to NF155 staining at the paranode (red, A). Triple staining (C  –  F) for voltage-gated sodium channels 
(blue, C), bound anti-NF155/NF186 mAb (green, D), and NF155 (red, E) confi  rm that the adoptively transferred mAb binds selectively at the node of 
Ranvier. (F) Merged image of (C  –  E). Deposition of the in vivo  –  injected antineurofascin mAb at the node of Ranvier is accompanied by the deposition of 
complement C9. Sections were stained with an Alexa Fluor 488  –  conjugated anti  –  mouse IgG2a antibody to identify bound antineurofascin mAb (green), 
and a rabbit anti  –  rat C9 antibody (red, G and H). Bars: 5     m.   JEM VOL. 204, October 1, 2007 
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exacerbate clinical disease. The inability of A12/18.1 to rec-
ognize NF155 in these animals is presumably related to its 
localization within the paranodal axo  –  glial junctional com-
plex. The antibody may be unable to penetrate into the junc-
tional complexes or, alternatively, access to the target epitope 
is blocked owing to local protein  –  protein interactions. How 
antibody binding to the node leads to loss of function in EAE 
remains to be clarifi  ed. Unlike autoantibody-mediated demy-
elination, the clinical defi  cit in this model is associated with 
neither enhanced infl  ammation nor demyelination. However, 
the codeposition of C9 with antibody suggests involvement 
of complement, as is the case in other autoantibody-mediated 
neurological diseases (  34, 35  ). This supposition is supported 
by our demonstration that A12/18.1 only mediates a func-
tional defi  cit in vitro in the presence of fresh serum, and that 
this eff  ect is abolished if the serum is heated at 56  °  C before the 
experiment. However, irrespective of the eff  ector mechanisms 
involved, antibody-mediated axonal injury and the resulting 
functional defi  cit are reversible. Not only did the majority of 
animals recover clinically, but      -APP-immunoreactivity also 
returns to background levels with recovery, and there was no 
evidence of axonal loss. This suggests that the node of Ranvier 
is relatively resistant to antibody-mediated damage. This may 
involve clearance of antibody  –  complement complexes by en-
docytosis or ectocytosis (  36  ), or up-regulation of complement 
inhibitors such as CD55 by neurons in EAE lesions (  37  ). 
  Our experiments demonstrate that neurofascin-specifi  c 
antibodies mediate axonal injury after recognition of NF186, 
but we cannot exclude they do not have other pathological 
eff  ects. The molecular architecture of the paranode is dis-
rupted after both experimental demyelination (  38  ) and in MS 
plaques (  39  –  41  ), indicating that NF155 may become acces-
sible to bind antibody in demyelinating lesions. Neurofascin-
specifi  c antibodies may also inhibit remyelination by binding 
to NF155 reexpressed on the surface of remyelinating ol-
igodendrocytes/oligodendrocyte processes (  42  ). Moreover, 
NF186 is not lost from the axonal surface after demyelination 
but is simply more diff  usely distributed (  40  ), suggesting that it 
will continue to provide a target for autoantibody-mediated 
attack in demyelinated lesions. Neurofascin is also expressed 
on myelinated fi  bers in the peripheral nervous system, sug-
gesting that it could also be involved in the pathogenesis 
of autoimmune-mediated peripheral neuropathies. In the cur-
rent study, we did not observe any enhanced      -APP immuno-
reactivity or C9 deposition in the peripheral nervous system, 
although some antibody was detected bound to nodes in root 
entry zones. The blood  –  nerve barrier is known to have a lim-
ited permeability to serum Ig  ’  s at these sites (  43  ), and in the 
absence of a local infl  ammatory response, diff  usion of antibody 
into the nerve is unable to initiate a functional defi  cit (  44  ). In 
the absence of peripheral nerve damage, the sudden death of 
some animals during the recovery phase of the disease cannot 
be explained satisfactorily, although it might refl  ect central auto-
nomic dysfunction. 
  We demonstrate that neurofascin-specifi  c antibodies medi-
ate axonal damage, impair neuronal conduction, and exacerbate 
  In vivo in animals with EAE, we demonstrate that anti-
bodies with this specifi  city bind selectively to NF186 at the 
node of Ranvier to initiate axonal injury in the CNS and 
  Figure 5.     Antineurofascin antibody disrupts nerve conduction 
in vitro. (A) An example of the field potential recorded under control 
conditions from the CA1 region of a rat hippocampal slice in a single slice 
using a single stimulus of the Schaffer collateral-commissural fi  bers every 
30 s (top trace) is shown. Perfusion of the antineurofascin mAb A12/18.1 
plus normal rat serum causes a decrease in the fi  ber volley amplitude 
(middle trace), which can be clearly seen when the traces are overlaid 
(bottom trace). (B) Time-course data showing the effect of A12/18.1 anti-
body and serum on the amplitude of the fi  ber volley (mean       SEM;   n     5). 
The horizontal line indicates application of antibody. (C) A decrease in 
fi  ber volley amplitude after a 1-h perfusion of the treatment is only seen 
when A12/18.1 is applied in the presence of fresh rat serum. There is no 
effect on the fi  ber volley amplitude if A12/18.1 and heat inactivated (HI) 
serum are applied or if a control IgG2a antibody and fresh serum are 
applied (  n     5 for all treatments). The dashed line indicates the control 
value against which the other values are measured. Signifi  cance is deter-
mined by a paired   t   test on the raw (not normalized) data. P = 0.012 for 
A12/18.1 antibody and fresh serum.     2370 AUTOANTIBODIES TO NEUROFASCIN INDUCE AXONAL INJURY | Mathey et al.
Invitrogen) and blotted to polyvinyldene difl  uoride membrane. Patients  ’   
sera were diluted 1:250 and detected with peroxidase-conjugated secondary 
reagents and enhanced chemiluminescence. 
  For two-dimensional gel electrophoresis, myelin glycoproteins were 
solubilized in a buff  er containing 7 M urea, 2 M thiourea, 4% CHAPS, 100 mM 
dithiothreitol, and 2% ampholytes. Glycoproteins were resolved on 17-cm 
IEF strips (pH range 3  –  10; Bio-Rad Laboratories) and separated in the 
second dimension with a 7% PAGE. After electrophoresis of duplicate gels 
that were run in parallel, one was silver stained (  50  ) and the other was blot-
ted to polyvinyldene difl  uoride membranes and immunoreactive proteins 
detected as described in the previous paragraph. Spots corresponding to 
  immunoreactive regions of the blot were excised from the silver-stained gel, 
digested with trypsin, and analyzed by matrix-assisted laser desorption ion-
ization time-of-fl  ight mass spectrometry (MALDI-MS). Proteins corre-
sponding to the cleaved fragments were identifi  ed by screening the National 
Center for Biotechnology Information database using the program Pro-
Found (Genomic Solutions). 
  ELISA.     96-well polyvinyl ELISA plates (Costar) were coated with 100      l 
of 5      g/ml rat NF155  ED   (R  &  D Systems) or BSA (Sigma-Aldrich) in PBS 
overnight at 4  °  C. Patient sera were diluted 1:200, and binding was detected 
with anti  –  human IgG labeled with alkaline phosphatase (Chemicon). The 
antigen-specifi  c response is plotted as (mean NF155  ED   OD   −   NF155  ED   SD)   −   
(mean BSA OD   3 BSA SD). 
  Affi   nity purifi  cation of anti-NF155  ED   antibodies.     500      g of recombi-
nant rat NF155  ED   was bound to an activated NHS column (GE Healthcare), 
according to the manufacturer  ’  s instructions. Plasma was adjusted to pH 7.4 
and run over the NF155  ED   column, followed by extensive washing with 
PBS. Bound Ig  ’  s were eluted with 0.1 M glycine, pH 2.7, and neutralized 
immediately with 1 M Tris, pH 9. 
  Flow cytometry analysis.     HeLa cells were transfected with NF186 in 
pEGFP  –  N1 (Clontech) or NF155 in pCDNA3.1 (Invitrogen; provided by 
P. Brophy, University of Edinburgh, Edinburgh, UK) using Lipofectamine 
(Invitrogen), according to the manufacturer  ’  s instructions. Stable high ex-
pressing cell lines were selected using G418. Surface expression of NF155 and 
NF186 was confi  rmed by immunocytochemistry and fl  ow cytometry using 
the panneurofascin mAb A12/18.1. For fl  ow cytometry, NF155-transfected, 
NF186-transfected, or untransfected HeLa cells were diluted in FACS buff  er 
(PBS/3% FCS) and plated out in 96-well plates at a density of 10  5   cells per 
well in the presence of mAb A12/18.1 or human antibody diluted to a con-
centration of 10      g/ml. After incubation for 30 min on ice, the cells were 
washed with FACS buff  er and incubated for a further 30 min on ice with 
anti  –  mouse IgG Alexa Fluor 488 (dilution 1:250; Invitrogen) or anti  –  human 
IgG Alexa Fluor 488 (dilution 1:250; Invitrogen). After washing with FACS 
buff  er, the staining was analyzed immediately on a fl  ow cytometer (FACS-
Calibur; BD Biosciences) using CellQuest Pro software (BD Biosciences). 
  Animal experiments.     All animal experiments were performed in Aberdeen 
with institutional (University of Aberdeen) and British Home Offi   ce ap-
proval. EAE was induced in female DA rats (6  –  8 wk old; Harlan) by adoptive 
transfer of 2       10  6   activated MOG  IgD  -specifi  c T cells, as previously described 
(  51  ). At the onset of clinical disease, rats were injected i.p. with either the 
NF155/186-specifi   c mAb A18/12 or a control mouse IgG2a antibody 
(Sigma-Aldrich). Animals were weighed and examined daily for clinical signs 
of EAE, which was scored using the following scale: 0.5, partial loss of tail 
tone; 1, complete tail atony; 2, hind limb weakness; 3, hind limb paralysis; 
4, fore limb paralysis; and 5, moribund. In addition, seven naive DA rats 
were injected i.p. with 500   μ  g antineurofascin mAb to investigate any possi-
ble eff  ects mediated in the absence of a preexisting CNS infl  ammation. 
  Immunohistology.     Animals were fi  xed in 4% paraformaldehyde via car-
diac perfusion. Brains and spinal cords were left in 4% paraformaldehyde 
for 30 min before immersion in 30% sucrose. Tissue was then embedded in 
clinical disease in an animal model of MS; however, are they 
relevant in human disease? For a circulating autoantibody 
response to mediate tissue damage within the CNS, two 
criteria must be met. First, the blood  –  brain barrier must be 
breached so that autoantibodies circulating in the blood can 
gain access to the CNS parenchyma (  12, 16, 45  ), and second, 
once within the CNS compartment, the antibody must be 
able to access and bind to its target antigens. In the case of 
the neurofascin-specifi  c autoantibody response in MS, these 
criteria are both met. First, MS is associated with an increased 
permeability of the blood  –  brain barrier to serum Ig  ’  s (  46  ). 
In the initial infl  ammatory phase of MS, this is most promi-
nent in areas of perivascular infl  ammation. However, there is 
also evidence that as the disease progresses patients develop 
chronic blood  –  brain barrier abnormalities that result in in-
creased leakage of serum protein into the CNS (  47, 48  ). This 
indicates that antineurofascin antibodies in the periphery will 
gain access to the CNS parenchyma. Second, the polyclonal 
neurofascin-specifi  c autoantibody response recognizes the na-
tive extracellular domain of NF186. As we demonstrate using 
mAb A12/18.1, these antibodies will bind to NF186 in vivo 
to exacerbate axonal injury and associated functional defi  cits 
in patients with MS. These eff  ects will be most pronounced 
in patients with high titer antibody responses to NF155/186 
and may have a considerable impact on disease progression. 
This may be the case in the 20  –  30% of MS with high titer 
antibody responses, but it should be noted that neurofascin-
specifi  c antibodies were also detected in occasional control 
donors. This lack of absolute disease specifi  city is not un-
expected and is similar to that reported for autoimmune re-
sponses to other CNS autoantigens in MS (  46  ). In summary, 
we identify neurofascin as a novel autoantigen in a subset of 
MS patients and demonstrate that neurofascin-specifi  c anti-
bodies can induce reversible axonal injury and conduction 
block in infl  ammatory demyelinating diseases of the CNS. 
These fi  ndings should open new perspectives for therapeutic 
inhibition of antibody-mediated axonal injury. 
  MATERIALS AND METHODS 
  Patients and control donors.     Sera from 74 patients were analyzed. These 
included 26 patients with MS, 17 patients with OINDs, 10 patients with 
noninfl  ammatory other neurological diseases, and 21 healthy blood donors. 
The MS patient group included 13 patients with defi  nite relapsing-remitting 
MS, 4 patients with a clinical isolated syndrome suggestive of MS, and 9 
patients with chronic progressive MS. The IgG fractions used to identify 
NF155 as a candidate autoantigen were isolated from patients undergoing 
immunoadsorption therapy (  28  ). Plasmapheresis samples were provided by 
L.-A. Hoff  mann, M. Krumbholz, T. Kümpfel, and H. Pellkofer (Ludwig-
Maximilians-University, Munich, Germany). This study was approved by an 
Ethical Committee of the University of Munich. 
  Purifi  cation of myelin glycoproteins.     Myelin was prepared according to 
the protocol described by Norton and Poduslo (  49  ). The myelin pellet was 
lyophilized and stored at   −  80  °  C. A myelin glycoprotein fraction was ob-
tained by lentil-lectin affi   nity chromatography according to the manufacturer  ’  s 
guidelines (GE Healthcare). 
  Gel electrophoresis, immunodetection, and mass spectrometry.   
  Myelin glycoproteins were separated in 4  –  12% polyacrylamide gels (Novex; JEM VOL. 204, October 1, 2007 
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optimal cutting temperature compound and snap frozen in isopentane/liquid 
nitrogen. To evaluate infl  ammation, sections were incubated with the anti-
bodies W3/13 (Serotec) and ED1 (Serotec) to stain infi  ltrating T cells and 
macrophages, respectively. The infl  ammatory index was calculated as the 
mean number of perivascular infl  ammatory infi  ltrates derived from an aver-
age of 15 complete cross sections of spinal cord of an individual animal. Axonal 
injury was visualized by      -APP staining (Chemicon). 
  For paranodal staining, sections were postfi  xed for 1 min in Bouin  ’  s fi  x-
ative. Before staining, 10-     m longitudinal and transverse spinal cord cryo-
sections were incubated in 10% normal goat serum/0.3% Triton X-100 in 
PBS for 1 h. Primary antibodies were applied for 1 h at room temperature or 
at 4  °  C overnight. After washing, the secondary antibodies were applied for 
1 h at room temperature, followed by washing and mounting in VECTA-
SHIELD Hardset (Vector Laboratories). The antibodies used in this study 
were as follows: rabbit NF155-F3 (1:1,000, specifi  c for the third fi  bronectin 
type III domain of NF155; a gift from P. Brophy) (  52  ), mouse pan-antisodium 
channel (1:100, IgG1; Sigma-Aldrich), and rabbit anti  –  rat C9 (1:1,000; gift 
from P, Morgan, Cardiff   University, Cardiff  , UK). Anti  –  mouse IgG  2a   Alexa 
Fluor 488 (1:500), anti  –  mouse IgG  1   Alexa Fluor 633 (1:500), and anti  –  rabbit 
Alexa Fluor 568 (1:500) were obtained from Invitrogen. Paraffi   n sections 
were prepared and evaluated as previously described (  53  ). 
  Confocal microscopy.     Images were captured using a laser scanning confo-
cal system (LSM510 META; Carl Zeiss MicroImaging, Inc.) coupled to an 
upright microscope (Axioplan2; Carl Zeiss MicroImaging, Inc.). Images were 
analyzed using LSM Image Viewer software (Carl Zeiss MicroImaging, Inc.). 
  Electrophysiology.     Young adult female Lewis rats (4  –  6 wk old) were 
killed, and the brains were removed and placed in chilled (4  –  5  °  C) oxygen-
ated artifi   cial cerebrospinal fl   uid (aCSF). The aCSF contained 124 mM 
NaCl, 3 mM KCl, 26 mM NaHCO  3  , 1.25 mM NaH  2  PO  4  , 10 mM   d-  glucose, 
1 mM MgSO  4  , and 2 mM CaCl  2   and was continuously bubbled with 95% 
O  2  /5% CO  2  . After dissecting free the hippocampus, 350-     m transverse 
slices were cut using a tissue chopper (McIlwain). Slices were stored in a 
holding chamber at room temperature before being transferred to an inter-
face-type recording chamber. Within the interface chamber, aCSF was con-
tinually perfused below the slice at a rate of 1  –  2 ml/min and at a constant 
temperature of 27  –  29  °  C. 
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